Evidence map›Paper›PMID 26136941›Full record

ArticleExperimental and therapeutic medicine2015

Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations.

Tengteng Wang, Tao Zhang, Xiaoxue Han, X I Liu, Naikang Zhou, Yang Liu

Abstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. [Computed tomography findings, clinicopathological features, genetic characteristics and prognosis ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. [Overview of Clinical Progress in Pulmonary Ground-glass Nodules].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016
    Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tengteng WangDepartment of Thoracic Surgery, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Tao ZhangDepartment of Thoracic Surgery, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Xiaoxue HanDepartment of Ultrasound, Chinese Capital Institute of Pediatrics, Beijing 100020, P.R. China.
X I LiuDepartment of Thoracic Surgery, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Naikang ZhouDepartment of Thoracic Surgery, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Yang LiuDepartment of Thoracic Surgery, Chinese PLA General Hospital, Beijing 100853, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to compare pathological diagnoses, as determined by the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification, with conventional radiological features. In addition, the present study aimed to evaluate the correlation among clinical characteristics, computed tomography (CT) images and gene mutation status in patients with stage IA adenocarcinoma of the lung. A total of 212 patients with stage IA lung adenocarcinoma were included in the study. The patients were classified into pure ground-glass opacity (pGGO), mixed GGO (mGGO) and solid GGO (sGGO) by CT imaging. Histological subtype was classified according to the IASLC/ATS/ERS classification of lung adenocarcinoma. In addition, epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma (KRAS) mutation assays were performed, and 36.8% of patients (78/212) were determined to have an EGFR mutation, while 8.5% of patients (18/212) were found to have a KRAS mutation. According to the IASLC/ATS/ERS classification, 44 cases were diagnosed as adenocarcinoma

Indexed as

gene mutationground-glass opacitylung adenocarcinoma

Identifiers

PMID26136941
PMCPMC4473664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.